Yipinhong Pharmaceutical

Yipinhong Pharmaceutical (USA) Limited is a U.S. subsidiary of Yipinhong Pharmaceutical Co., Ltd. (300723.SZ). Yipinhong Pharmaceutical Co., Ltd. (300723.SZ) is an innovative biopharmaceutical enterprise that integrates research and development, production, and sales. The company adheres to quality and innovation as the driving forces for development, focusing on pediatric medications and chronic disease drugs. In terms of pediatric drugs, the company has built multiple formulation platforms suitable for children's medications and developed core technologies such as drug micronization technology, taste-masking granulation technology, delayed-release technology, and pellet-coating technology. In the area of chronic disease medications, the company has established an oral sustained and controlled release formulation research laboratory and an industrial production technology transformation center, forming R&D and production capabilities for advanced sustained and controlled release technologies such as matrix type, osmotic pump type, and membrane-controlled type. The company has over 20 sustained-release, controlled-release, and innovative drug products under development, covering areas such as cardiovascular and cerebrovascular diseases, nervous system diseases, immune system diseases, and endocrine system diseases.